Recent Updates
Recently added Catalysts
CSCI

Condensed Interim Consolidated Financial Statements As at JUNE 30, 2020 and for the three-month AND SIX-MONTH periodS ended JUNE 30, 2020 and 2019 ( In thousands of US dollars) (Unaudited) Condensed Interim Consolidated

Key Takeaway: Interim Consolidated Financial Statements at JUNE 30, 2020 and for the three-month AND SIX-MONTH periodS ended JUNE 30, 2020 and 2019 thousands of US dollars) Interim Consolidated Financial Statements at JUNE 30, 2020 and for the three-month AND SIX-MONTH periodS ended JUNE 3

Full Press Release Details

Interim Consolidated Financial Statements
at JUNE 30, 2020 and for the three-month AND SIX-MONTH periodS ended JUNE 30, 2020 and 2019
thousands of US dollars)
Interim Consolidated Financial Statements
at JUNE 30, 2020 and for the three-month AND SIX-MONTH periodS ended JUNE 30, 2020 and 2019
Condensed Interim Consolidated Statements of Financial Position 3
Condensed Interim Consolidated Statements of Changes in Shareholders' Equity (Deficiency) 5
Condensed Interim Consolidated Statements of Comprehensive Income (Loss) 7
Condensed Interim Consolidated Statements of Cash Flows 8
Notes to Condensed Interim Consolidated Financial Statements 9
Interim Consolidated Statements of Financial Position
thousands of US dollars)
June 30, 2020 December 31, 2019
$ $
ASSETS
Current Assets
Cash and cash equivalents 6,743 7,838
Trade and other receivables (note 5) 814 658
Inventory 375 1,203
Prepaid expenses and other current assets (note 21) 1,123 1,211
Total current assets 9,055 10,910
Restricted cash equivalents 313 364
Right of use assets (note 6) 190 582
Property, plant and equipment 25 35
Identifiable intangible assets 32 40
Goodwill (note 7) 8,054 8,050
Total assets 17,669 19,981
LIABILITIES
Current liabilities
Payables and accrued liabilities (note 8) 1,697 2,148
Provision for restructuring and other costs (note 9) 107 418
Income taxes payable - 1,448
Current portion of deferred revenues 596 991
Current portion of lease liabilities (note 10) 119 648
Current portion of warrant liability (note 11) 12 6
Total current liabilities 2,531 5,659
Deferred revenues 148 185
Lease liabilities (note 10) 103 255
Warrant liability (note 11) - 2,249
Employee future benefits (note 12) 13,678 13,788
Non-current provision for restructuring and other costs (note 9) 278 308
Total liabilities 16,738 22,444
SHAREHOLDERS' EQUITY (DEFICIENCY)
Share capital 226,724 224,528
Warrants (note 13) 4,237 -
Other capital 89,467 89,806
Deficit (319,592 ) (316,891 )
Accumulated other comprehensive income ("AOCI") 95 94
Total shareholders' equity (deficiency) 931 (2,463 )
Total liabilities and shareholders' equity (deficiency) 17,669 19,981
and contingencies (note 20)
accompanying notes are an integral part of these condensed interim consolidated financial statements.
by the Board of Directors
/s/ Carolyn Egbert /s/ Pierre-Yves Desbiens
Carolyn Egbert Chair of the Board Pierre-Yves Desbiens Director
Interim Consolidated Statements of Changes in Shareholders' Equity (Deficiency)
the three MONTHS ended june 30, 2020 and 2019
thousands of US dollars, unaudited)
Common shares (number of) Share capital Warrants Other capital Deficit AOCI Total
$ $ $ $ $ $
Balance - April 1, 2020 23,472,771 226,413 - 89,694 (314,724 ) 304 1,687
Net (loss) - - - - (3,450 ) - (3,450 )
Other comprehensive loss:
Foreign currency translation adjustments - - - - - (209 ) (209 )
Actuarial (loss) on defined benefit plan (note 12) - - - - (1,418 ) - (1,418 )
Comprehensive (loss) - - - (4,868 ) (209 ) (5,077 )
Reclassification of warrant liability to equity (note 11(b)) - - 4,237 - - - 4,237
Issuance of common shares, net (note 13) 111,300 311 - (362 ) - - (51 )
Share-based compensation costs (note 14) - - - 135 - - 135
Balance - June 30, 2020 23,584,071 226,724 4,237 89,467 (319,592 ) 95 931
Common shares (number of) Share capital Warrants Other capital Deficit AOCI Total
$ $ $ $ $ $
Balance - April 1, 2019 16,440,760 222,335 - 89,437 (315,427 ) 95 (3,560 )
Net income - - - - 206 - 206
Other comprehensive loss:
Foreign currency translation adjustments - - - - - (110 ) (110 )
Actuarial (loss) on defined benefit plan (note 12) - - - - (756 ) - (756 )
Comprehensive (loss) - - - - (550 ) (110 ) (660 )
Issuance of common shares 191,650 805 - - - - 805
Share-based compensation costs - - - 387 - - 387
Balance - June 30, 2019 16,632,410 223,140 - 89,824 (315,977 ) (15 ) (3,028 )
Interim Consolidated Statements of Changes in Shareholders' Equity (Deficiency)
the six months ended june 30, 2020 and 2019
thousands of US dollars, unaudited)
Common shares (number of) Share capital Warrants Other capital Deficit AOCI Total
$ $ $ $ $ $
Balance - January 1, 2020 19,994,510 224,528 - 89,806 (316,891 ) 94 (2,463 )
Net (loss) - - - - (2,671 ) - (2,671 )
Other comprehensive loss:
Foreign currency translation adjustments - - 1 1
Actuarial (loss) on defined benefit plan (note 12) - - - (30 ) - (30 )
Comprehensive (loss) - (2,701 ) 1 (2,700 )
Reclassification of warrants upon registration (note 11(b)) - - 4,237 - - - 4,237
Issuance of common shares and warrants, net (note 13 and note 11(a), respectively) 3,589,561 2,196 - (362 ) - - 1,834
Share-based compensation costs (note 14) - - - 23 - - 23
Balance - June 30, 2020 23,584,071 226,724 4,237 89,467 (319,592 ) 95 931
Common shares (number of) Share capital Warrants Other capital Deficit AOCI Total
$ $ $ $ $ $
Balance - January 1, 2019 16,440,760 222,335 - 89,342 (309,781 ) 11 1,907
Net (loss) - - - - (4,705 ) - (4,705 )
Other comprehensive loss:
Foreign currency translation adjustments - - - - - (26 ) (26 )
Actuarial (loss) on defined benefit plan (note 12) - - - - (1,491 ) - (1,491 )
Comprehensive (loss) - - - - (6,196 ) (26 ) (6,222 )
Issuance of common shares 191,650 805 - - - 805
Share-based compensation costs - - - 482 - - 482
Balance - June 30, 2019 16,632,410 223,140 - 89,824 (315,977 ) (15 ) (3,028 )
accompanying notes are an integral part of these condensed interim consolidated financial statements.
Interim Consolidated Statements of Comprehensive Loss
the three AND SIX months ended JUNE 30, 2020 and 2019
thousands of US dollars, except share and per share data)
Three months ended Six months ended
June 30 June 30
2020 2019 2020 2019
$ $ $ $
Revenues (note 4)
Royalty income 10 8 24 21
Product sales - 129 1,016 129
Supply chain 40 39 81 45
Licensing revenue 18 18 37 36
Total revenues 68 194 1,158 231
Operating expenses
Cost of sales 12 101 874 101
Research and development costs 189 571 508 1,099
General and administrative expenses 1,141 1,923 2,265 3,560
Selling expenses 199 495 447 799
Restructuring costs (note 9) - 773 - 773
Impairment of right of use asset - 64 - 401
Gain on modification of building lease (notes 6 and 10) (34 ) - (219 ) -
Impairment of prepaid asset - - - 169
Total operating expenses (note 14) 1,507 3,927 3,875 6,902
Loss from operations (1,439 ) (3,733 ) (2,717 ) (6,671 )
Gain (loss) due to changes in foreign currency exchange rates 130 (6 ) 26 58
(Loss) gain on change in fair value of warrant liability (note 11) (2,139 ) 3,926 331 1,865
Other finance (costs) income (2 ) 19 (311 ) 43
Net finance (costs) income (2,011 ) 3,939 46 1,966
Net (loss) income (3,450 ) 206 (2,671 ) (4,705 )
Other comprehensive (loss):
Items that may be reclassified subsequently to profit or loss:
Foreign currency translation adjustments (209 ) (110 ) 1 (26 )
Items that will not be reclassified to profit or loss:
Actuarial (loss) on defined benefit plans (note 12) (1,418 ) (756 ) (30 ) (1,491 )
Comprehensive (loss) (5,077 ) (660 ) (2,700 ) (6,222 )
Net (loss) income per share [basic and diluted] (0.15 ) 0.01 (0.12 ) (0.28 )
Weighted average number of shares outstanding (note 19):
Basic 23,515,579 16,622,415 22,519,497 16,532,090
Diluted 23,515,579 17,260,016 22,519,497 16,532,090
accompanying notes are an integral part of these condensed interim consolidated financial statements.
Interim Consolidated Statements of Cash Flows
the three AND SIX months ended june 30, 2020 and 2019
thousands of US dollars, except share and per share data)
Three months ended Six months ended
June 30, June 30,
2020 2019 2020 2019
$ $ $ $
Cash flows from operating activities
Net (loss) income for the period (3,450 ) 206 (2,671 ) (4,705 )
Items not affecting cash and cash equivalents:
Loss (gain) on change in fair value of warrant liability (note 11) 2,139 (3,926 ) (331 ) (1,865 )
Transaction costs of warrants issued and expensed as finance cost - - 310 -
Provision for restructuring costs utilized (note 9) (21 ) 790 (348 ) 773
Depreciation and amortization 39 70 146 136
Impairment of right of use asset - 64 - 401
Impairment of prepaid asset - - - 169
Gain on modification of building lease (notes 6 and 10) (34 ) - (219 ) -
Share-based compensation costs 89 595 (23 ) 690
Employee future benefits (note 12) 50 2 99 136
Amortization of deferred revenues (23 ) (18 ) (37 ) (36 )
Foreign exchange (loss) on items denominated in foreign currencies (84 ) (4 ) (32 ) (49 )
Gain on disposal of property, plant and equipment (2 ) - (2 ) (3 )
Other non-cash items 22 - 7 -
Interest accretion on lease liabilities (note 10) (4 ) (18 ) (15 ) (38 )
Payment of income taxes (637 ) - (1,448 ) -
Changes in operating assets and liabilities (note 15) (494 ) 69 (290 ) (785 )
Net cash used in operating activities (2,410 ) (2,170 ) (4,854 ) (5,176 )
Cash flows from financing activities
Issuance of common shares and warrants (notes 13 and 11, respectively) - 314 4,500 314
Transaction costs (note 13) (11 ) - (611 ) -
Payments on lease liabilities (note 10) (41 ) (159 ) (199 ) (310 )
Net cash provided by (used in) financing activities (52 ) 155 3,690 4
Cash flows from investing activities
Proceeds from disposal of property, plant and equipment 6 - 6 -
Change in restricted cash equivalents 50 - 50 50
Net cash provided by investing activities 56 - 56 50
Effect of exchange rate changes on cash and cash equivalents (33 ) 341 13 293
Net change in cash and cash equivalents (2,439 ) (1,674 ) (1,095 ) (4,829 )
Cash and cash equivalents - Beginning of period 9,182 11,357 7,838 14,512
Cash and cash equivalents - End of period 6,743 9,683 6,743 9,683
accompanying notes are an integral part of these condensed interim consolidated financial statements.
to Condensed Interim Consolidated Financial Statements
at JUNE 30, 2020 and for the three AND SIX months ended JUNE 30, 2020 and 2019
in thousands of US dollars, except share/option/warrant and per share/option/warrant data and as otherwise noted) (Unaudited)
of business and liquidity
Zentaris Inc. ("Aeterna Zentaris" or the "Company") is a specialty biopharmaceutical company commercializing
and developing therapeutics and diagnostic tests. The Company's lead product, Macrilen (macimorelin), is the first
and only United States Food and Drug Administration ("FDA") and European Commission approved oral test indicated for
the diagnosis of patients with adult growth hormone deficiency ("AGHD"). Macrilen (macimorelin) is currently
marketed in the U.S. through a license and assignment agreement (the "License Agreement") with Novo Nordisk A/S ("Novo").
Aeterna Zentaris is also pursuing the development of macimorelin for the diagnosis of child-onset growth hormone deficiency ("CGHD"),
an area of significant unmet need. In addition, we are actively pursuing business development opportunities for the commercialization
of macimorelin in Europe and the rest of the world in addition to other non-strategic assets to monetize their value.
Company's principal focus is on the commercialization of Macrilen (macimorelin) and it currently does not have any
other approved products. Under the terms of License Agreement, Novo is funding 70% of the pediatric clinical trial submitted to
the European Medicines Agency ("EMA") and FDA, the Company's sole development activity. In November 2019, Novo
contracted the Company's wholly owned German subsidiary ("AEZS Germany") to provide supply chain services for
the manufacture of Macrilen (macimorelin). In April 2020, we announced the results from AEZS-130-P01 ("Study P01")
to establish a dose that can both be safely administered to pediatric patients and cause a clear rise in growth hormone concentration
in subjects ultimately diagnosed as not having growth hormone deficiency. The Company plans to proceed with the pivotal second
study, AEZS-130-P02 ("Study P02"), with an expected start date in the first quarter of 2021 and an expected completion
date in July 2022, according to the pediatric investigation plan ("PIP") agreement with the EMA. Study P02 is designed
to investigate the diagnostic efficacy and safety of macimorelin acetate in pediatric patients from 2 years of age to 18 years
of age with suspected growth hormone deficiency.
at June 30, 2020, a substantial portion of the Company's cash is held in AEZS Germany, the Company's principle operating
subsidiary. AEZS Germany is the counter-party to the License Agreement described above with Novo, and as such, for generating
future revenue earned under the License Agreement. Management considers the cash resources available to AEZS Germany in executing
its obligations under the License Agreement. In the event the current and medium term liabilities of AEZS Germany exceed the fair
values ascribed to its assets, under German solvency laws, it may no longer be possible for AEZS Germany's operations to
continue or for AEZS Germany to transfer cash to Aeterna Zentaris or its U.S. subsidiary, if needed.
2020, the COVID-19 pandemic began causing significant financial market declines and social dislocation. The situation is dynamic
with various cities and countries around the world responding in different ways to address the outbreak. The spread of COVID-19
may impact the Company's operations, including the potential interruption of our clinical trial activities and the Company's
supply chain, or that of the Company's licensee. For example, the COVID-19 outbreak may delay enrollment in the Company's
clinical trials due to prioritization of hospital resources toward the outbreak, and some patients may be unwilling to be enrolled
in the Company's trials or be unable to comply with clinical trial protocols if quarantines impede patient movement or interrupt
healthcare services, which would delay the Company's ability to conduct clinical trials or release clinical trial results
and could delay the Company's ability to obtain regulatory approval and commercialize the Company's product candidates.
The pandemic may also impact the ability of the Company's suppliers to deliver components or raw materials on a timely basis
or at all. In addition, hospitals may reduce staffing and reduce or postpone certain treatments in response to the spread of an
infectious disease. The Company's licensee may be impacted due to significant delays of diagnostic activities in the U.S.
To date, the Company has not experienced significant business disruption from COVID-19.
unaudited condensed interim consolidated financial statements have been prepared in accordance with International Financial Reporting
Standards as issued by the International Accounting Standards Board ("IFRS") applicable to the preparation of interim
financial statements, including IAS 34, Interim Financial Reporting. These unaudited condensed interim consolidated financial
statements should be read in conjunction with the Company's annual consolidated financial statements as at and for the year
ended December 31, 2019.
unaudited condensed interim consolidated financial statements were approved by the Board of Directors (the "Board")
accounting policies in these condensed interim consolidated financial statements are consistent with those presented in the Company's
annual consolidated financial statements except as noted below:
Company accounts for share purchase warrants that meet the fixed-for-fixed criteria as equity-settled.
share units ("DSUs) are classified as other capital. The Company grants DSUs to members of its Board of Directors who are
not employees or officers of the Company. DSUs cannot be redeemed until the holder is no longer a director of the Company and
are considered equity-settled instruments. Under the terms of the DSU agreement, the DSUs vest immediately upon grant. The value
attributable to the DSUs is based on the market value of the share price at the time of grant and share based compensation expense
is recognized in general and administrative expenses on the consolidated statements of loss and comprehensive (loss) income. At
the time of redemption, each DSU may be exchanged for one common share of the Company.
consideration received by the Company in connection with the exercise of DSUs is credited to share capital. Any other capital
component of the share-based compensation is transferred to share capital upon the issuance of shares.
preparation of condensed interim consolidated financial statements in accordance with IFRS requires management to make judgments,
estimates and assumptions that affect the reported amounts of the Company's assets, liabilities, revenues, expenses and
related disclosures. Judgments, estimates and assumptions are based on historical experience, expectations, current trends and
other factors that management believes to be relevant at the time at which the Company's condensed interim consolidated
financial statements are prepared.
reviews, on a regular basis, the Company's accounting policies, assumptions, estimates and judgments in order to ensure
that the condensed interim consolidated financial statements are presented fairly and in accordance with IFRS. Revisions to accounting
estimates are recognized in the period in which the estimates are revised and in any future periods affected.
Last updated: Aug 6, 2020